Member Info for solstace

At their best lol 😆

Yesterday at the DDR inhibitors

https://x.com/Parsortix/status/1882417049940742159?t=wOCUMhCtBtPhmiRpIbZtQA&s=19

Angle's x post yesterday with link to webinar

https://x.com/Parsortix/status/1884662707237834888?t=duzzb0BOKSwnuVurEajYog&s=19

Could have a strong order book after next weeks webinar! Illumina have dedicated the whole show to Angle, lots of exposure to Illumina's vast network of customers!!!!

And before you spout some carp about buying in at the bottom and selling at the top don't bother, no one buys your horse shi*

Oh dear Sharebel, I told you yesterday NFX would place when you came on this board banging on about a placing here! IMM have no need to do a placing!!!!!!!!!!!!!!!!

Good luck at NFX you'll need it, gonna be locked in there for a long time to come!!!!!

The webinar is the first joint marketing initiative for ANGLE and Illumina

It will save 10,000's of lives annually

ANGLE has already reported (RNS announcement dated 4 January 2024) on the successful development of a workflow for the dual analysis of CTC-DNA and ctDNA using the Illumina platform with a third-party assay kit (now under option for exclusive licence by ANGLE). In the forty-seven-patient study across four cancer types (breast, lung, ovarian and prostate), a significant number of patients had clinically relevant mutations found in their CTCs that were not present in ctDNA from the same blood draw. This data further validates these findings.

Andrew already saying that it's available to illumina customers

https://x.com/investwisely321/status/1884622231738737001?t=v1OP_L5X8NS8fIVV5K3Pvw&s=19

They'll be up and about over the pond shortly and I bet this will end up on quiet a few radars, big thumbs up from Nadaq listed Illumina!

ANGLE (AGL), a liquid biopsy company announce new, successful results for the Company’s dual circulating tumour DNA (ctDNA) and CTC-DNA workflow using, for the first time, an end-to-end Illumina solution for analysis. AGL said it sees a substantial opportunity for both ANGLE and Illumina to work closely together and are grateful to Illumina for the opportunity to present its DNA dual analysis data at their webinar hosted by the highly rated EACR.

Comment: All cashed up, AGL is in a purple patch in terms of development, something which looks as though it could achieve transformational results.

Cash runway of £12m with sales growing 30+% last year.

I can't state how important this is for Angle to have Illumina showing a massive vote of confidence!

It's important to THEM! As stated in the RNS verbatim :-)

A £17bn Mcap Nasdaq listed company has assigned their entire European Association for Cancer Research (EACR) webinar to ANGLE's findings

This is huge for Angle......"Illumina has assigned"

As a result of these positive findings and their importance to both companies, Illumina has assigned their entire European Association for Cancer Research (EACR) webinar to ANGLE's findings. The webinar, entitled 'Complementary insights: Exploring the dual analysis of circulating tumour cells and circulating DNA', will present ANGLE's results on 6 February 2025 at 16:00 GMT.

Think certain people opened a spread bet or went short when the RNS was released and are now s*it ting themselves as this ain't gonna go the way they thought!

Sea of blue, big volume, little movement = P.L.A.C.I.N.G

GLA

Sharebels in NFX MASSIVE placing being worked over there!

Run back to NFX, this afternoon will be ALL about IMM :-)

😂😂😂